CLVS:NSD-Clovis Oncology, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.20

Change

+0.19 (+3.16)%

Market Cap

USD 0.62B

Volume

5.81M

Average Target Price

USD 10.33 (+66.67%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-5.38 (-3.58%)

USD59.42B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+0.60 (+0.28%)

USD56.27B 21.03 14.64
REGN Regeneron Pharmaceuticals, Inc

-9.43 (-2.01%)

USD50.14B 15.34 12.06
ALXN Alexion Pharmaceuticals, Inc

+1.56 (+1.02%)

USD33.62B 56.22 34.28
BGNE BeiGene, Ltd

+2.43 (+0.73%)

USD32.08B N/A N/A
RPRX Royalty Pharma plc

+0.28 (+0.60%)

USD29.34B 22.60 14.73
SGEN Seagen Inc

-2.01 (-1.28%)

USD28.45B 46.60 41.48
BNTX BioNTech SE

+2.20 (+1.96%)

USD27.59B -99,999.99 N/A
GMAB Genmab A/S

-1.57 (-4.28%)

USD25.02B 26.59 2.93
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CLVS

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.17% 64% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.17% 64% D 74% C
Trailing 12 Months  
Capital Gain -17.11% 21% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.11% 21% F 9% F
Trailing 5 Years  
Capital Gain -68.53% 22% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.53% 22% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain 18.39% 58% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.39% 58% F 73% C
Risk Return Profile  
Volatility (Standard Deviation) 142.05% 16% F 7% F
Risk Adjusted Return 12.95% 46% F 41% F
Market Capitalization 0.62B 61% D- 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -1.92 15% F 56% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -63.49% 49% F 16% F
Return on Assets -31.38% 42% F 12% F
Debt to Equity Ratio -370.00% 97% A+ 98% A+
Technical Ratios  
Short Ratio 4.17 41% F 29% F
Short Percent 35.76% 1% F 5% F
Beta 1.74 33% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector